- Home
- GTEC vs AYTU Comparison
GTEC vs AYTU Comparison
Compare GTEC & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | AYTU |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 23.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GTEC | AYTU |
|---|---|---|
| Price | $1.24 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 1.1M | 128.1K |
| Earning Date | 11-07-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | $63,696,000.00 |
| Revenue This Year | $5.64 | N/A |
| Revenue Next Year | $3.93 | $47.32 |
| P/E Ratio | $1.46 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.58 | $0.95 |
| 52 Week High | $2.92 | $3.07 |
Technical Indicators
Market Signals| Indicator | GTEC | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 51.17 |
| Support Level | $0.98 | $2.60 |
| Resistance Level | $1.61 | $2.77 |
| Average True Range (ATR) | 0.23 | 0.15 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 58.50 | 12.90 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.